Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PICKRCC: Abemaciclib + Sunitinib in Metastatic RCC
NCT03905889Phase 1Terminated
- Sponsor
- Brown University
- Start
- Jun 2019
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of abemaciclib in metastatic renal cell carcinoma (mRCC), sponsored by Brown University. Primary endpoints: Maximum Tolerated Dose, Toxicity Assessment and 1 more. Started Jun 2019; status: terminated.
02
Drugs
abemaciclib
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on NCT03905889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03905889.